Do statins increase the risk of diabetes or is it guilt by association?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 2, 2014, Pages 140-145

  Mogadam, Michael ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

diacylglycerol in myocytes and hepatocytes; glucose transporter type 4; myocytes' mitochondrial melanocortins; serine phosphorylation of insulin receptors

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL OBESITY; DIABETES MELLITUS; DIET; DRUG USE; DYSGLYCEMIA; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HEART PROTECTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MEDICAL LITERATURE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDENTARY LIFESTYLE;

CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LIPIDS; MALE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896868377     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000050     Document Type: Review

References (22)

1. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; 172:144-152
2. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-Analysis of randomized statin trials. Lancet 2010; 375:735-742
3. Danaei G, García Rodríguez LA, Fernandez Cantero O, HernánMA. Statins and risk of diabetes: An analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 2013; 36:1236-1240
4. Ridker P, Pradhan A, MacFadyen J, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012; 380:565-571
5. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: A population-based study. BMJ 2013; 346:f2610. (ISSN: 1756-1833.
6. Waters DD, Ho JE, Demicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57:1535-1545
7. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-Analysis. JAMA 2011; 305:2556-2564
8. Waters DD, Ho JE, Boekholdt SM. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013; 61:148-1526
9. Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012; 60:1231-1238. (ISSN: 1558-3597
10. Ma Y, Culver A, Rossouw J, et al. Statin therapy and the risk for diabetes among adult women: Do the benefits outweigh the risk? Ther Adv Cardiovasc Dis 2013; 7:41-44. (ISSN: 1753-9455
11. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care setting. Ann Intern Med 2013; 158:526-534
12. Yeboah J, Bertoni AG, Herrington DM, et al. Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2011; 58:140-146
13. Francis BH, Song X, Andrews LM, et al. Progression to type 2 diabetes, healthcare utilization, and cost among prediabetic patients with or without comorbid hypertension. Curr Med Res Opin 2011; 27:809-819. (ISSN: 1473-4877
14. Kokkinos P, Faselis C, Myers J, et al. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidemia: A cohort study. Lancet 2013; 381:394-399
15. Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. J Clin Lipidol 2013; 7:304-384
16. Phan BA, Muñoz L, Shadzi P, et al. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels ((100 mg/dl): A combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study Am J Cardiol 2013 111 352-355.
17. Chalasoni N, Younossi Z, Lavin JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592-1609
18. Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 2011; 140:144-152
19. Singh S, Singh PP, Sing AG, Murad MH. Statins are associated with a reduced risk of hepatocellular cancer: A systemic review and meta-Analysis. Gastroenterology 2013; 144:323-332
20. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010; 303:2058-2064
21. Stone NJ, Robinson JG, Lichtenstein AH, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: Synopsis of the 2013 ACC/AHA Cholesterol Guideline. Ann Intern Med ; Published online 28 January 2014 doi:10.7326/M14-0126.
22. Hennekens CH, Demets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-Analyses, or subgroup analyses. JAMA 2009; 302:2361-2362